Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8698904 | 1.00 | SIGMAR1 (0.50) | SIGMAR1MAPT | |
| SCHEMBL11776188 | 1.00 | SIGMAR1 (0.50) | SIGMAR1MAPT | |
| Hydrochloric Acid SCHEMBL11778162 | 0.97 | SIGMAR1 (0.48) | SIGMAR1MAPT | |
| Hydrochloric Acid SCHEMBL11778155 | 0.97 | SIGMAR1 (0.48) | SIGMAR1MAPT | |
| SCHEMBL13443289 | 0.85 | GAA (0.48) | SIGMAR1 | |
| SCHEMBL20328234 | 0.84 | SIGMAR1 (0.51) | SIGMAR1MAPT | |
| SCHEMBL15366366 | 0.83 | SIGMAR1 (0.47) | SIGMAR1MAPT | |
| SCHEMBL29615483 | 0.82 | TLR7 (0.46) | — | |
| SCHEMBL5496544 | 0.81 | SIGMAR1 (0.46) | SIGMAR1MAPT | |
| SCHEMBL5858231 | 0.81 | SIGMAR1 (0.49) | SIGMAR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11518764-B2 | Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-12-06 | — | — | US | disclosed |
| US-20200331921-A1 | INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2020-10-22 | — | — | US | disclosed |
| WO-2019153080-A1 | INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2019-08-15 | — | — | WO | disclosed |
| US-8399488-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399488-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120122850-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122850-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-8119796-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119796-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110281851-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20100137325-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137325-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-7728144-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC (US) | 2010-06-01 | — | — | US | disclosed |
| US-7728144-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC (US) | 2010-06-01 | — | — | US | disclosed |
| US-7683173-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683173-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20090076026-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-03-19 | — | — | US | disclosed |
| US-20090076026-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-03-19 | — | — | US | disclosed |
| US-7479562-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2009-01-20 | — | — | US | disclosed |
| US-7479562-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2009-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11518764-B2 | Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction | BCL6, BCL6B, BCL3 | SIGMAR1 4315/4885MAPT 2333/4885 |
| US-20200331921-A1 | INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | BCL6, BCL6B, BCL3 | SIGMAR1 4547/4885MAPT 2192/4885 |
| US-20090076026-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM3, CHRM5 | SIGMAR1 303/4885MAPT 4731/4885 |
| US-20100137325-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM3, CHRM5 | SIGMAR1 303/4885MAPT 4731/4885 |
| US-20110281851-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM3, CHRM5 | SIGMAR1 311/4885MAPT 3983/4885 |
| US-20120122850-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM3, CHRM5 | SIGMAR1 311/4885MAPT 3983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.